Eric Joseph
Stock Analyst at JP Morgan
(1.24)
# 3,547
Out of 4,945 analysts
134
Total ratings
34.48%
Success rate
-12.68%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $41.55 | +54.03% | 4 | Jun 3, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.64 | - | 5 | May 20, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $45 → $44 | $3.03 | +1,352.15% | 3 | May 9, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $9.43 | -25.77% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $48.70 | +37.58% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.35 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.58 | - | 4 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $30 | $10.56 | +184.09% | 7 | Jan 29, 2025 | |
| IGMS IGM Biosciences | Upgrades: Neutral | n/a | $1.27 | - | 8 | Jan 13, 2025 | |
| VIR Vir Biotechnology | Maintains: Neutral | $10 → $14 | $4.44 | +215.32% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $36.02 | +97.11% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $43 | $27.77 | +54.84% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $11.68 | +225.34% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $1.55 | +1,383.87% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $8.91 | +90.80% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $3.39 | +519.47% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $48 | $17.63 | +172.26% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $7.69 | +30.04% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.08 | - | 4 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.69 | +790.21% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.35 | +155.32% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $5.64 | +77.30% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $4.35 | +152.87% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $50.09 | -18.15% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $10.55 | +847.87% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.55 | +809.09% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.48 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $6.77 | +62.48% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $10.85 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $4.65 | +2,480.65% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $7.80 | +3,746.15% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $4.12 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.85 | +386.49% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.29 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.79 | +1,405.38% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $1.07 | +1,114.95% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.54 | +1,937.04% | 3 | Nov 14, 2018 |
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $41.55
Upside: +54.03%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.64
Upside: -
Rocket Pharmaceuticals
May 9, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $3.03
Upside: +1,352.15%
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $9.43
Upside: -25.77%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $48.70
Upside: +37.58%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.58
Upside: -
Nurix Therapeutics
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $10.56
Upside: +184.09%
IGM Biosciences
Jan 13, 2025
Upgrades: Neutral
Price Target: n/a
Current: $1.27
Upside: -
Vir Biotechnology
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $4.44
Upside: +215.32%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $36.02
Upside: +97.11%
Nov 25, 2024
Maintains: Overweight
Price Target: $30 → $43
Current: $27.77
Upside: +54.84%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $11.68
Upside: +225.34%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $1.55
Upside: +1,383.87%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $8.91
Upside: +90.80%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $3.39
Upside: +519.47%
Aug 7, 2024
Maintains: Overweight
Price Target: $45 → $48
Current: $17.63
Upside: +172.26%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $7.69
Upside: +30.04%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.08
Upside: -
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.69
Upside: +790.21%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.35
Upside: +155.32%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $5.64
Upside: +77.30%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $4.35
Upside: +152.87%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $50.09
Upside: -18.15%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $10.55
Upside: +847.87%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.55
Upside: +809.09%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.48
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $6.77
Upside: +62.48%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $10.85
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $4.65
Upside: +2,480.65%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $7.80
Upside: +3,746.15%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $4.12
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.85
Upside: +386.49%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.29
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.79
Upside: +1,405.38%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $1.07
Upside: +1,114.95%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.54
Upside: +1,937.04%